Putnam FL Investment Management Co. Sells 1,618 Shares of Regeneron Pharmaceuticals Inc (REGN)

Putnam FL Investment Management Co. trimmed its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 8.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 18,557 shares of the biopharmaceutical company’s stock after selling 1,618 shares during the quarter. Putnam FL Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $6,977,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. Ark Investment Management LLC grew its stake in Regeneron Pharmaceuticals by 78.8% during the second quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 544 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $206,000. AHL Partners LLP acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $1,544,000. Macquarie Group Ltd. grew its stake in Regeneron Pharmaceuticals by 1.6% during the second quarter. Macquarie Group Ltd. now owns 31,608 shares of the biopharmaceutical company’s stock worth $15,524,000 after buying an additional 513 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in Regeneron Pharmaceuticals by 176.1% during the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 428 shares in the last quarter. 65.69% of the stock is currently owned by institutional investors and hedge funds.

Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $344.00 on Thursday. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals Inc has a 1 year low of $319.50 and a 1 year high of $543.55. The company has a market cap of $36,400.33, a P/E ratio of 31.51, a P/E/G ratio of 1.28 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the consensus estimate of $4.52 by $0.71. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period last year, the company earned $3.04 EPS. The firm’s revenue was up 28.9% compared to the same quarter last year. analysts predict that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current year.

A number of equities research analysts have issued reports on REGN shares. Canaccord Genuity reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Barclays downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $450.00 to $395.00 in a research note on Friday, October 20th. Guggenheim reiterated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Finally, Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Friday, November 3rd. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $470.84.

ILLEGAL ACTIVITY WARNING: “Putnam FL Investment Management Co. Sells 1,618 Shares of Regeneron Pharmaceuticals Inc (REGN)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2018/02/08/putnam-fl-investment-management-co-sells-1618-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply